What You Should Know:
Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced expanded capabilities designed to help employers and health plans manage rising demand for anti-obesity medication such as…
Continue Reading
What You Should Know:
– Tiny Health, a pioneer in at-home gut microbiome testing for babies, announced today the successful closing of an $8.5M Series A funding round.
– Led by Spero Ventures, this round brings…
Continue Reading
Food-as-medicine companies are none too thrilled about recent comments made by Kellogg CEO Gary Pilnick.
In a CNBC interview, the multimillionaire executive encouraged families struggling to put food on the table to turn to cereal…
Omada, a virtual healthcare provider, announced Tuesday that it is expanding its GLP-1 companion solution to include musculoskeletal exercise programming and member-level reporting for employers, payers and pharmacy benefit managers.
San Francisco-based Omada serves employers,…
Background: The Health eLiteracy for Prevention in General Practice trial is a primary health care–based behavior change intervention for weight loss in Australians who are overweight and those with obesity from lower socioeconomic areas….
Continue Reading
Rob MacNaughhton, CEO at Calibrate
What You Should Know:
– Calibrate, the leading clinician-guided and value-based obesity treatment program, today announced the appointment of Rob MacNaughton as its new Chief Executive Officer.
– Calibrate’s strategic direction under…
Continue Reading
Obesity-focused healthcare technology company Intellihealth has hired Annie Lorenzo as its executive vice president of clinical operations. She will manage the clinical operations personnel at Intellihealth’s clinical services affiliate, Flyte Medical.
Flyte offers users access to…
According to the CDC, 42% of Americans are considered obese. There aren’t enough obesity medicine specialists to see them all. Brand medications are on the FDA shortage list and natural methods such as diet…
Continue Reading
GLP-1 medications like Ozempic and Wegovy remain in high demand and continue to make headlines, even among mainstream media outlets. As the healthcare industry watches closely to see how payers decide to cover the…
Continue Reading
News and social media are saturated with articles about the demand for and shortage of glucagon-like peptide-1 (GLP-1) drugs marketed for weight loss. The best-known of these drugs is semaglutide, sold under the brand…
Continue Reading
